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Testicular cancers are the most common malignancy in young
adult males. The aetiology of testicular germ cell tumours
(TGCTs) of adolescents and adults remains unknown, but certain
risk factors such as cryptorchidism (Batata et al, 1982) and carci-
noma in situ (CIS) (van der Maase et al, 1986) are known to be
important predisposing risk factors. TGCTs are divided into two
entities; seminomatous and non-seminomatous germ cell tumours
(Mostofi and Sobin, 1977). Seminoma (SE) is composed of cells
that are considered the neoplastic counterparts of the primitive
germ cells (gonocytes). Non-seminomatous germ cell tumours
(NSGCTs) have embryonal carcinoma cells as their stem cell,
which can differentiate into extra embryonic (trophoblast and
yolk-sac), embryonic (somatic) tissue or a mixture of embryonal
carcinoma and both embryonic and extra-embryonic tissues. SE
and NSGCT elements may occur simultaneously as combined
tumours, or they may be geographically separate or mixed,
suggesting that they could share a common developmental
pathway via a common precursor. CIS is a neoplastic growth of
totipotential cells that, like seminoma, resemble primitive germ
cells. It has been proposed that CIS originates from malignant
transformation of foetal gonocytes and there is consensus that CIS
is the precursor for most testicular germ cell tumours in adults,
with the exception of spermatocytic seminoma (Jacobsen et al,
1981; Skakkebæk et al, 1987).
While it is now generally accepted that CIS is the precursor of
TGCTs (Jacobsen et al, 1981; Skakkebæk et al, 1987), the devel-
opmental relationship between SE and NSGCTs remains poorly
understood (Damjanov, 1989). Two main hypotheses have been
proposed. The first model is based on the former hypothesis of
Pierce and Abell (1970) that assumes SE and NSGCT are indepen-
dently derived from CIS. According to this theory, the distinct
neoplastic pathway for the formation of SE diverges from that of
NSGCT at an early stage (Kiss and Jubasz, 1985; Sesterhenn,
1985; Mostofi, 1986). The alternative linear progression model,
which is based on the theories of Ewing (1911) and Friedman
(1951), assumes that both SE and NSGCTs share a common origin
in CIS and develop along a single neoplastic pathway. Seminoma
may be either an end-stage in differentiation or an intermediate in
the development of NSGCT (Raghavan et al, 1982; Oliver, 1987;
Oosterhuis et al, 1989). The linear progression model is further
supported by the presence of SE with NSGCT characteristics
(Oliver et al, 1987; Czaja and Ulbright, 1992), the finding of
NSGCT elements in the metastases of apparently pure primary SE
(Bredael et al, 1982) and from DNA-flow cytometry and cytoge-
netic analysis (Castedo et al, 1989a; 1989b; Oosterhuis et al, 1989;
de Jong et al, 1990; Looijenga et al, 1993; Gillis et al, 1994).
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Summary Testicular germ cell tumours (TGCTs) may arise through a process of multi-step carcinogenesis, and loss of heterozygosity (LOH)
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carcinoma in situ (CIS) to either seminoma (SE) and/or non-seminomatous germ cell tumour (NSGCT). Universal amplification has been
performed on 87 TGCT specimens and 36 samples of CIS cells microdissected from single paraffin-embedded tumour sections from 40
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microsatellite markers were used to assay these samples for LOH at candidate regions selected from the literature, mapping to 3q, 5q, 9p,
11p, 11q, 12q, 17p and 18q. Construction of deletion maps for each of these regions identified common sites of deletion at 3q27–q28, 5q31,
5q34–q35, 9p22–p21 and 12q22, which correlate with allelic losses we have also observed in the precursor CIS cells. Evidence for allelic loss
at 3q27–q28 was observed in all of the embryonal carcinoma samples analysed. We conclude that inactivation of gene(s) within these regions
are likely to be early events in the development and progression of TGCTs. These results also provide molecular evidence in support of the
hypothesis that SE is an intermediate stage of development within a single neoplastic pathway of progression from CIS precursor cells to
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doi: 10.1054/ bjoc.2000.1334, available online at http://www.idealibrary.com on In over 85% of cases, the formation of isochromosome 
12p, resulting in the over-representation of the short arm of
chromosome 12, is the only consistent abnormality noted in
TGCTs (Atkin and Baker, 1982). The remaining isochromosome
12p-negative TGCTs invariably exhibit gain of 12p-sequences
revealed by fluorescence in situ hybridization (Rodriguez et al,
1993; Suijkerbuik et al, 1993). In addition, about 5% of all TGCTs
show specific amplifications corresponding to 12p11.1–12.1
(Mostert et al, 1998). The gene or genes that are over-represented
on 12p, and that directly contribute to the development of germ
cell tumours, have not yet been identified.
Inactivation of tumour suppressor genes plays a central role in
the development and progression of many human cancers. In inva-
sive TGCTs, loss of heterozygosity (LOH) at numerous loci on
virtually every chromosome has been observed, making it difficult
to ascertain which genetic events are the most crucial to carcino-
genesis (Murty et al, 1994; Peng et al, 1995). It is likely that
TGCTs arise through a process of multi-step carcinogenesis and
that LOH at specific loci is an important early event. Evidence for
a minimal region of deletion at 12q22 (Murty et al, 1996a) as well
as at 5p15, 5q11 and 5q34–q35 (Murty et al, 1996b) has been
reported, though regions of consistent loss have not yet been
defined. It is therefore difficult to determine which, if any, of the
genes contained within these regions demonstrating LOH are
fundamental to the development of invasive testicular cancer.
To further characterize the pattern of allelic loss in TGCTs it is
necessary to investigate specific sub-populations of enriched
TGCT and CIS cells for LOH. The use of microsatellite markers
for such investigations has been hampered due to limitations and
difficulties associated with the PCR amplification of DNA isolated
from paraffin-embedded tissue. These difficulties include a high
rate of random PCR failure and the poor quality, yield and storage
properties of the isolated DNA samples (Shibata et al, 1992;
Crisan and Mattson, 1993). This study is the first to investigate the
molecular genetic changes in SE and NSGCTs as well as the
adjacent CIS cells, using universal genomic amplification as a
means of circumventing the technical difficulties. The primer
extension pre-amplification (PEP) (Zhang et al, 1992) has been
applied to achieve multiple PCR assays on single cells and has
recently been shown to be a useful tool for extending limited DNA
samples (Casa and Kirkpatrick, 1996). We have modified the
existing PEP protocol to generate genomic DNA from sub-
populations of enriched TGCT cells and CIS cells microdissected
from small regions of paraffin-embedded formalin-fixed tissue
sections (Faulkner et al, 1998).
In this study, universal amplification has been applied to speci-
mens of CIS cells and TGCT cells of varying histology microdis-
sected from single paraffin-embedded tumour sections. These
included multiple specimens of CIS and TGCT cells of varied
histology microdissected from each patient whose tumours repre-
sented the pathological continuum observed in TGCTs. This may
provide new information about the pathogenetic relationships
between these elements of CIS, SE and NSGCT. Several chromo-
somal regions, including those where consistent LOH in TGCTs
has previously been demonstrated, were selected from the litera-
ture as candidates for assessment of allele status (Lothe et al, 1993;
Murty et al, 1994a; 1994b; 1996a; 1996b; Peng et al, 1995;
International Testicular Cancer Linkage Consortium, 1998). Based
on the pattern of allelic losses, we now define deletion maps of
chromosomal regions mapping to 3q, 5q, 9p, 11p, 11q, 12q, 17p
and 18q for these pre-amplified CIS and TGCT specimens.
MATERIALS AND METHODS
Preparation of DNA from enriched sub-populations of
cells
All TGCT specimens were collected at the operating theatre and
directly fixed overnight at room temperature in 4% buffered
formalin. Consecutive histological sections were cut from
paraffin-embedded tumour blocks of these specimens. The first
and last sections (4 µ m) cut were de-waxed, hydrated, stained
with haematoxylin and eosin (H&E) and cover-slipped, while the
intermediate section (10 µ m) was left unstained and fixed to a
microscope slide. Sub-populations of TGCT, CIS or constitu-
tional cells were identified and marked on both H&E-stained
slide sections following microscopic examination, ensuring no
significant differences were evident between the composition of
the marked cellular regions. After careful alignment with the
corresponding H&E-stained slide, the selected cellular regions
were physically removed from a single unstained section using a
scalpel blade. The area of the cells microdissected from a single
slide section typically ranged from 1–10 mm2 depending on the
number of cells contained within a suitable sub-population.
These cells were boiled at 95° C for 10 min and then incubated
for 2 h at 65° C in a conventional PCR buffer containing
Proteinase K at a final concentration of 1000 µ g ml–1, followed
by heat inactivation at 85° C for 15 min. Aliquots of this digest
solution provided the target DNA template for universal amplifi-
cation.
Universal DNA amplification
Duplicate universal amplification reactions were performed for
each specimen under paraffin oil in 60 µ l volumes containing 1 ×
Stoffel buffer (Perkin-Elmer, Norwalk, CT, USA), 200 pmols of
random 12-mer oligonucleotide, 10 U AmpliTaq DNA
Polymerase, Stoffel Fragment (Perkin-Elmer), 200 µ M of each
dNTP, 5 mM MgCl2, and DNA template. Templates were 10 µ l of
the digest solution of cells dissected from paraffin tissue sections.
Water blanks were included as contamination checks for each
amplification series. Thermal cycling conditions were as follows;
92° C (4 min), 40 cycles of 92° C (1 min), 25° C (2 min), 30° C (30
s), 35° C (30 s), 40° C (30 s) and 72° C (2 min) followed by a final
extension step of 72° C (15 min). The thermal ramping rate was set
at 0.25° C s–1 between the 25° C and 30° C steps. A slow ramp rate
at low annealing temperature was used to enhance annealing of
oligonucleotides to the template DNA. All thermal cycling was
performed in a Corbett Research (Sydney, NSW, Australia) FTS-
960 Thermal Sequencer (96-well plate format). The duplicate
universal amplification products were pooled for each specimen
prior to assaying for LOH.
Loss of heterozygosity assay
LOH was determined using PCR to identify polymorphisms in
microsatellite regions of patient constitutional and tumour DNA
at a given locus. Aliquots of the pooled universal amplification
products generated from DNA isolated from sub-populations 
of SE, NSGCT, CIS and constitutional control DNA were
amplified by PCR using specific oligonucleotide primers
flanking each microsatellite marker loci. PCR was performed in
10 µ l volumes containing 0.4 U AmpliTaq DNA polymerase
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dCTP (3000 Ci mmol–1), 20 µ M dNTPs, 1 × PCR buffer
(Perkin-Elmer) and either 1 µ l of universal amplification
product or pre-amplified water blank as a contamination check.
DNA and control samples were amplified using general thermal
cycling conditions as follows; 92° C (3 min), 30 cycles of 92° C
(1 min), 48° C (10 s), 50° C (20 s), 54° C (20 s), 58° C (20 s),
62° C (10 s) and 72° C (2 min) followed by a final extension step
of 72° C (15 min). All microsatellite repeat markers were
obtained from Research Genetics (Huntsville, AL, USA).
Differences in the number of repeat sequences between PCR
product alleles were resolved using denaturing 7%, 19:1 poly-
acrylamide gel electrophoresis, with the amplified PCR prod-
ucts being detected via autoradiography. Constitutional DNA
was required for LOH analysis to assess normal allele status at
any given locus (i.e. heterozygosity or homozygosity). Allelic
imbalances were scored visually by comparison of allele inten-
sity in heterozygote patients with obvious reduction of one
allele in tumour DNA compared with the intensity of constitu-
tional alleles. Densitometric analysis of typical examples of
allelic imbalance showed that alleles with less than 50% reduc-
tion in band intensity had been conservatively scored as
retaining heterozygosity. After standardizing the tumours
against their respective paired constitutive controls allelic
imbalance was able to be interpreted as LOH.
Deletion of a specific chromosomal region was defined by the
observation of LOH at one or more microsatellite loci located at
these chromosomal regions with the following conditions. The
observation of LOH at a single microsatellite locus was not
deemed sufficient to score as a deletion without further evidence
of chromosomal arm monosomy of LOH at adjacent loci. Only a
single round of microsatellite PCR was performed for samples
showing evidence of LOH as the deletion mapping approach we
have used reduces the reliance upon a single result and hence
decreases the chance of a false interpretation of allelic imbalance
at any specific chromosomal region. All samples were scored for
LOH without knowledge of the map position of the microsatellite
locus being assessed.
RESULTS
Universal amplification of tumour samples
Universal amplification was performed on 36 sub-populations of
CIS cells and 87 TGCT specimens comprising 39 seminomas, 13
teratomas, 17 embryonal carcinomas, 12 yolk sac and six mixed
NSGCTs isolated from single tumour sections from 40 patients.
These included specimens from 24 patients whose tumours repre-
sented the pathological continuum observed in TGCTs, including
two patients with a combined tumour histology. Multiple speci-
mens of CIS and TGCT cells of varied histology were able to be
microdissected from each of these 24 individual patients.
Multiple (~100) microsatellite markers could be reliably ampli-
fied from the universal amplification products generated by this
modified protocol, without the difficulties generally associated
with the PCR analysis of DNA isolated directly from paraffin-
embedded tissue. The efficiency of this universal amplification
schedule was conservatively estimated at 100-fold amplification.
There was no evidence of preferential allelic amplification
observed in the constitutional control samples.
Investigation of deletion at specific chromosomal
regions
A panel of 77 microsatellite markers was used to assay the pre-
amplified samples for LOH by PCR at chromosomal regions
mapping to 3q, 5q, 9p, 11p, 11q, 12q, 17p and 18q (Figure 1).
Allele status was assessed at a minimum of three and a maximum
of 25 polymorphic loci for each chromosomal region (Table 1).
Among these, only four microsatellite loci (D12S64, D17S946,
D17S393 and IGF1) demonstrated the retention of heterozygosity
for all informative tumour specimens. Comparison of the extent of
genetic loss indicated that NSGCTs to have a higher fractional
allelic loss (FAL) (mean 0.23) than SE (mean 0.17). There were no
significant differences between the mean FAL observed for each
NSGCT histological sub-type. LOH was the most frequent for
microsatellite loci mapping to chromosome 9. The pattern of
allelic loss for several tumours indicated the presence of chromo-
somal arm monosomy or large deletions affecting 11p (4%), 5q
(10%), 3q (11%), 18q (10%) and 9p (23%). Monosomy was not
observed in the chromosomal arms 11q, 12q or 17p in any of the
tumours examined.
Chromosomal deletion maps were constructed from the pattern
of microsatellite allelic losses observed in each TGCT patient.
These pre-amplified specimens were assessed for the presence of
allelic loss at commonly deleted chromosomal regions located to
3q27–q28, 5q31, 5q34–q35, 9p22–p21, 11p15.5, 11p13, 11q13,
12q22, 17p13 and 18q21.1. A deletion was defined by the observa-
tion of LOH at one or more microsatellite loci located at these
chromosomal regions. The observation of LOH at a single
microsatellite locus was not deemed sufficient to score as a dele-
tion without further evidence of chromosomal arm monosomy or
LOH at adjacent loci. The incidence of deletion at each of these
chromosomal regions is summarized in Table 2. Losses were 
noted at every chromosomal region in SE and for all regions
except 11q13 in NSGCTs. None of these chromosomal regions
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Figure 1 Illustration of representative loss of heterozygosity (LOH)
observed at various microsatellite loci in. TGCTs and CIS specimens. 
(A) LOH at D5S1475 in three tumour specimens; LOH at D9S162 (B) and
D5S1456 (C) in two tumour specimens with retention of heterozygosity in the
associated CIS; (D) LOH at D5S1456 in the second CIS specimen only with
retention of heterozygosity in the tumour and other CIS specimen; (E) LOH at
D12S393 in two tumours and the first CIS specimen with retention of
heterozgosity in the second CIS. Low intensity bands in alleles denoted as
demonstrating LOH were attributed to the presence of constitutional DNA
contaminating the tumour DNA specimen (C = carcinoma in situ; N = normal
control; T = tumour. Arrows indicate alleles demonstrating LOH)732 SW Faulkner et al
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Table 1 Summary of percentage LOH observed in TGCTs at individual microsatellite loci
Locus Location Heterozygous Percentage Locus Location Heterozygous Percentage
tumours LOH tumours LOH
(n) (n)
D3S1268 3q25.2–q26.2 48 19 D11S922 11p15.5 46 15
D3S1262 3q27 42 26 TH 11p15.5 23 13
D3S1288 3q27 36 31 D11S988 11p15.5 46 7
D3S1265 3q27–qter 50 38 D11S926 11p15.4 26 12
D3S1272 3q27–qter 29 31 D11S915 11p15.1–p14.1 28 18
D3S1311 3q27–qter 42 21 D11S914 11p13 14 29
D11S907 11p13.3 41 7
D5S421 5q22–q23 60 17 FGF3 11q13.3 38 13
D5S622 5q23–q31 22 14 INT2 11q13.3 29 3
D5S393 5q31 39 33 D11S911 11q13–q23 26 4
D5S402 5q 31 16 –– – –
CSF1R-T 5q31–q33.2 40 23 D12S64 – 49 0
CSF1R 5q31–q33.2 27 7 D12S82 12q21–q22 50 6
D5S209 5q 21 10 D12S95 12q 47 2
D5S412 5q32–q33 42 19 D12S377 12q 21 5
D5S378 5q33 47 26 D12S58 12q22 49 12
D5S529 5q34 54 30 D12S393 12q22 45 38
D5S621 5q34 30 10 D12S296 12q22 41 32
D5S415 5q34 42 15 D12S1074 12q22 38 29
D5S671 5q34–q35 42 33 D12S346 12q22 56 13
D5S1713 5q34–q35 41 27 IGF1 – 15 0
D5S1475 5q34–q45 48 23 D12S78 12q23 39 15
D5S1456 5q34–q35 45 33 D12S84 12q23 40 13
D5S1402 5q34–q35 50 42 D12S79 12q22–qter 46 13
D5S805 5q34–q35 43 16 D12S378 12q23 54 24
D5S504 5q34–q35 38 26 D12S63 – 50 18
D5S400 5q34–q35 22 5 D12S367 12q–qter 46 7
D5S429 5q35 30 23 –– – –
D5S498 5q35 51 16 D17S1289 17p13 49 20
D5S211 5q35 39 15 TP53 17p13 35 17
D5S408 5q35 53 26 D17S793 – 33 0
GABRA1 5q35–qter 55 27 D17S946 – 22 0
D9S168 9p24–p22 57 54 D18S65 18q12.2–q12.3 39 15
D9S156 9p23–p22 39 26 D18S46 18q21.1 26 19
D9S268 9p23–p22 33 27 DCC 18q21.1 23 39
D9S285 9p23–p22 48 46 D18S64 18q21.32 44 25
D9S162 9p22–p21 49 37 D18S61 18q22.3 49 12
D9S171 9p21 36 42 D18S554 18q22.1–qter 57 19
D9S161 9p21 19 21 D18S70 18q23 71 25
D9S104 9p21 35 31 –– – –
Chromosomal regions and microsatellite markers defining regions of common deletion indicated in bold typeface. The relative microsatellite marker cytogenetic
locations and map positions were deduced using the GDB (http://www.gdb.org), GeneMap 99 (http://www.ncbi.nlm.nih.gov/genemap) and CHLC linkage
groupings by interval distribution (http://www.chlc.org)
Table 2 Regions of common deletion defined by patterns of microsatellite allelic loss
Defined Flanking markers Tumours Non- CIS/ CIS/
region showing 1 or seminoma Seminoma NSGCT SE
more losses at showing showing showing showing
this region (%) loss (%) loss (%) lossa (%) lossb (%)
3q27–q28 D3S1288–D3S1265 44 58 33 8 0
5q31 D5S393–CSF1R-T 29 23 34 13 6
5q34–q35 D5S1456–D5S1402 45 53 36 19 7
9p22–p21 D9S285–D9S171 51 64 38 15 13
11p15.5 D11S922–D11S988 13 13 13 0 0
11p13 D11S907–D11S914 18 21 15 0 10
11q13 FGF3–INT2 4 0 8 0 0
12q22 D12S58–D12S346 44 66 25 43 25
17p13 D17S1289–TP53 22 25 19 0 0
18q21.1 D18S46–DCC 46 41 48 0 0
aCIS cells from NSGCT bCIS cells from SEdemonstrated preferential deletion in either SE or NSGCT (Table
2). However, loss of one or more microsatellite loci mapping to
3q27–q28 was observed in all 10 embryonal carcinoma specimens
(Table 3), while teratomas and yolk-sac tumours each exhibited
loss of this region in only two of six cases. Some heterogeneity in
the observed regional chromosome losses was evident between the
sub-populations of cell isolates from patients with multiple speci-
mens of CIS (mean 13%), SE (mean 8%) or NSGCT (mean 9%).
Deletion of at least one of these chromosomal regions was
observed for every TGCT, with the exception of a single SE (data
not shown). The four SE tumour specimens and corresponding
CIS specimen isolated from this TGCT showed retention of
heterozygosity at all informative regions. Deletion of one or more
of the chromosomal regions 3q27–q28, 5q31, 5q34–q35,
9p22–p21, 11p13 and 12q22 was observed in the CIS specimens of
several patients representing the pathological continuum observed
in TGCTs. The allelotype of deletions observed in both the CIS
specimens and associated TGCT components of these patients are
summarized in Table 4. The individual components of the two
TGCTs with a combined histology demonstrated similar patterns
of allelic loss at multiple chromosomal regions (Table 5). Allelic
deletion at chromosomal region 9p21 was observed in a single CIS
specimen and in both the NSGCT and SE tumour components of
the first combined tumour. All of these TGCT specimens showed
additional losses of 18q21 as well as an accumulation of deletions
at 3q27–q28 and 12q22. There was only a single loss noted at
18q21 in the SE component of the second combined tumour and
no losses in either of the associated CIS specimens. All four of the
NSGCT components for this combined histology TGCT demon-
strated loss of 3q27–q28 in addition to deletion at other chromo-
somal regions including 18q21.
DISCUSSION
The ability to assay specific sub-populations of enriched TGCT
and CIS cells for LOH at multiple sites provides a valuable
allelotyping tool for determining clonal relationships and for iden-
tifying any critical losses required for tumour progression. This
study is the first to investigate the early molecular genetic changes
in CIS and the associated SE and NSGCT cells. The universal
amplification protocol we have used to achieve this has potential
errors with regard to preferential allelic amplification generating
false-positive LOH results in the pre-amplified DNA specimens.
However, previous experiments have demonstrated that universal
amplification products are an accurate representation of the allelic
ratio of the original DNA sample, since no evidence of preferential
allelic amplification was observed (Faulkner and Leigh, 1998).
Recently, the accuracy of this approach has been confirmed by
others (Paulson et al, 1999). In addition, the comparison of alleles
from the pre-amplified tumour specimens with those of the 
pre-amplified constitutional control samples, which did not
demonstrate preferential allelic amplification, further minimizes
the possibility of false-positive LOH results being generated by
universal amplification.
In this study of TGCTs, a high degree of genetic loss was
evident at many sites throughout the genome. Our results identify
a novel site of frequent deletion at 5q31 and confirm the results of
previous investigations noting regions of common deletion in
TGCTs at 3q27–28, 5q34–q35, 9p22–p21, 11p15.5, 11p13, 11q,
12q22, 17p13 (TP53) and 18q21.1 (DCC) (Lothe et al, 1993;
Murty et al, 1994a 1994b; 1996a; 1996b; Peng et al, 1995;
International Testicular Cancer Linkage Consortium, 1998). The
5q31 chromosomal region has previously been implicated in
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Table 3 Summary of allelic losses from individual tumours showing loss at 3q27–q28 in embryonal carcinoma and associated
TGCT and CIS specimens
Tumour
histology Result for each chromosomal region
3q27–q28 5q31 5q34–q35 9p22–p21 11p15 11p13 11q13 12q22 17p13 18q21
EC                          
SE                          
SE                           
SE –                         
CIS                             
CIS –                           
EC                        –
EC                        –
EC                           
EC                            
SE                             
CIS                            –
CIS                            –
EC                    
CIS                              
EC                          
CIS                              
TE                       –
EC                         –
EC                         –
EC                    –    –
YST                          –
  = allelic deletion;    = retention of heterozygosity; – = uninformative at this chromosomal region (homozygosity, no result or not
done); CIS = carcinoma in situ; EC = embryonal carcinoma; SE = seminoma; TE = teratoma; YST = yolk-sac tumour. Specimens
grouped by tumour histology and CIS sub-populations isolated from individual TGCTs with allelic losses at 3q27–q28 in ECTGCTs due to synteny with the murine chromosome 18 where the
teratoma susceptibility gene (Ter) has been mapped (Asada et al,
1994). More importantly, deletion of 3q27–q28, 5q31, 5q34–q35,
9p22–p21, 11p13 and 12q22 was also noted in CIS cells, which
has not been previously described.
Considering the high frequency of loss and evidence of losses in
CIS, the regions of loss observed at 3q27–q28, 5q31, 5q34–q35,
9p22–p21 and 12q22 are of particular interest. Losses of all five
noted regions were observed in all histological subtypes,
suggesting an important role for potential genes located at these
sites in the development of male GCTs. Our results suggest that
loss or inactivation of gene(s) located within the 3q27–q28 deleted
region appears essential for the development of embryonal carci-
noma while loss of this region is not required for the development
of teratoma or yolk-sac tumour (Table 3). Familial linkage studies
have previously identified 3q27–q28 as a candidate region
containing putative gene(s) involved in the development of
TGCTs (International Testicular Cancer Linkage Consortium,
1998). Loss of these putative genes may contribute to the inability
of these pluripotent embryonal carcinoma cells to differentiate and
thereby represent the formation of pure null-potent embryonal
carcinoma. Taken together these findings may represent an impor-
tant step in the identification of critical genes involved in the
development of TGCTs and more specifically the development of
embryonal carcinoma.
A degree of heterogeneity was evident in the chromosomal
losses identified between sub-populations of cells for the patients
with multiple specimens of CIS, SE or NSGCT. One possible
explanation for this observation is that several genes may be
involved in a multi-step mechanism of carcinogenesis and clonal
reprogramming acting in both CIS and TGCTs. There were no data
to suggest that loss of one or more specific regions in either CIS or
734 SW Faulkner et al
British Journal of Cancer (2000) 83(6), 729–736 © 2000 Cancer Research Campaign
Table 4 Summary of allelic losses from individual tumours showing losses in CIS and associated TGCT specimens
Tumour 3q27–q28 5q31 5q34–q35 9p22–p21 11p15 11q13 11p13 12q22 17p13 18q21
histology
TE –         –––   ––
TE –         –––       –
EC –         –––      –
EC –         –––       –
YST –         –––      –
NSGCT          –––      –
CIS            –––      –
CIS          –––       –
CIS             –––      –
CIS             –––      –
TE               –    
YST               –    
CIS                  –        
CIS          –       –        
SE                 –    –   
SE              ––         
CIS                 –         
SE                             
SE                              
CIS                              
CIS                             
CIS                             
SE                 –       
SE                 –       
CIS                   –        
SE            –        
SE            –        
CIS                –            
CIS                –      –   
TE         –       –
YST         –       –
CIS         –    –         –
CIS –       –    –         –
SE                  –    –   
SE                  –         
CIS                             
NSGCT                           
CIS                             
CIS                           
SE              –         
SE               –         
SE –            –          –
CIS                –            
CIS               –          –
  = allelic deletion;    = retention of heterozygosity; – = uninformative at this chromosomal region (homozygosity, no result or not done); CIS = carcinoma in
situ; EC = embryonal carcinoma; NSGCT = mixed NSGCT; SE = seminoma; TE = teratoma; YST = yolk-sac tumour. Specimens grouped by tumour histology
and CIS sub-populations isolated from individual patients with allelic losses in CISinvasive tumour is required for the preferential development of
either SE or NSGCT, with the noted exception of 3q27–q28 in
embryonal carcinoma. These data support the previously proposed
model for a single neoplastic pathway of progression from CIS
precursor cells to NSGCT with SE as an intermediate stage of
development (Ewing, 1911; Friedman, 1951; Raghavan et al,
1982; Oliver et al, 1987; Oosterhuis et al, 1989).
The inability of SE to express embryonic differentiation
suggests that specific chromosomal regions retained in these
tumours may contain genes regulating gonocytic differentiation. A
marked increase in loss at both 9p22–p21 and 12q22 was observed
in NSGCTs compared to SE. Deletion or inactivation of genes
located at these regions could represent loss of negative regulatory
elements for the expression of embryonic differentiation. The
absence of allelic losses in CIS for either TP53 or DCC suggests
that loss of these genes may be a late event involved in the
progression and clonal growth of an invasive tumour, rather than
an early event involved in the carcinogenesis of TGCTs.
Chromosome deletions of 17p and 18q have been well character-
ized as late events in the development of colorectal carcinoma
(Vogelstein et al, 1988).
DNA flow cytometry has shown that NSGCTs have a lower
DNA ploidy value than SE, leading to speculation that tumour
progression in TGCTs may be associated with a net non-random
loss of chromosomes in SE leading to NSGCT (Oosterhuis et al,
1989; Fosså et al, 1991; De Graaf et al, 1992). We have observed a
higher mean fractional allelic loss (FAL) for NSGCT when
compared to SE, which is consistent with these observations of
chromosome loss in NSGCT. Unlike a previous study, we find no
significant difference between the FAL for teratomas when
compared to embryonal carcinoma (Murty et al, 1994a).
The pathogenetic relationships between the subtypes of
TGCTs were explored by an allelotype analysis of the chromo-
somal deletions in CIS and the associated SE or NSGCT cells.
Assessment of the clonal relationships between the specimens of
CIS and TGCT elements for the combined histology tumours
provided further evidence for the clonal ‘reprogramming’ of SE
into NSGCT by the accumulation of genetic losses as outlined by
the linear progression model (Ewing, 1911; Friedman, 1951;
Raghavan et al, 1982; Oliver et al, 1987; Oosterhuis et al, 1989)
(Table 5). This clonal relationship could be traced directly from
the different CIS and SE specimens through to NSGCT (EC) in
the first case of combined tumour. The tumour components of the
second combined histology TGCT also appeared to be derived
from a monoclonal origin. Although no losses were observed in
either of the CIS specimens for this TGCT, there was evidence of
clonal ‘reprogramming’ occurring in the SE specimen to the
more advanced, though related, NSGCT (EC) components.
Combined tumours may therefore represent heterogeneous sub-
populations of SE and NSGCT cells progressing from related
CIS clones at various stages of progression through a single
neoplastic pathway.
Out data has demonstrated a variety of allelic losses in the sub-
populations of CIS and TGCT cells, including deletions in sub-
populations of CIS or TGCT not observed in the other associated
TGCT cells (Table 4). This tumour heterogeneity might also be
considered as evidence of clonal progression occurring within the
different regions of the tumour. The observation of this phenom-
enon in CIS suggests that clonal progression is occurring even at
this early stage of carcinogenesis. These data support the previ-
ously proposed model that sub-populations of CIS cells may accu-
mulate mitotic errors in multiple genes that represent the unknown
genetic switch to develop into an invasive tumour, which may
represent the formation of SE. Alternatively, some CIS may
undergo clonal ‘reprogramming’ by loss or inactivation of the crit-
ical genes responsible for the maintenance of gonocytic differenti-
ation. These CIS may then evolve directly into NSGCT following
the initiation event, thereby bypassing the SE intermediate (for
review, see Oosterhuis and Looijenga, 1993). The increased loss of
12q22 we have observed in CIS from NSGCTs compared to CIS
from their SE counterparts may represent the loss of such critical
regulatory genes residing within this chromosomal region.
Evidence for the under-representation of chromosome 12 and 15 in
CIS adjacent to NSGCT when compared to CIS adjacent to SE has
previously demonstrated the progressive karyotypic evolution of
CIS by chromosome loss (Looijenga et al, 1993; Gillis et al, 1994).
We speculate that the SEs exhibiting a degree of loss at the
commonly deleted regions comparable to NSGCTs may represent
highly malignant SE still under gonocytic differentiation control
not yet able to ‘reprogramme’ to an embryonal lineage. The single
Carcinoma in situ and testicular germ cell tumours 735
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Table 5 Summary of deletion allelotype for the CIS, SE and NSGCT components of TGCT in combined histology tumours
Tumour
histology Result for each chromosomal region
3q27–q28 5q31 5q34–q35 9p22–p21 11p15 11p13 11q13 12q22 17p13 18q21
EC                          
SE                          
SE                           
SE –                         
CIS                             
CIS –                           
EC                        –
EC                        –
EC                           
EC                            
SE                             
CIS                            –
CIS                            –
  = allelic deletion;    = retention of heterozygosity; – = uninformative at this chromosomal region (homozygosity, no result or not done); CIS = carcinoma in
situ; EC = embryonal carcinoma; SE = seminoma. Specimens grouped by tumour histology and CIS sub-populations isolated from individual patients with a
TGCT with the histology of a combined tumourTGCT with no losses may represent a SE at the early stages of
clonal progression with low malignant potential.
We conclude that deletion of gene(s) within the regions of
common deletion at 12q22, 5q34–q35, 5q31, 3q27–q28 and
9p21–p22 are early events in the carcinogenesis of TGCTs, and
that SE is an intermediate stage of development within a single
neoplastic pathway of progression from CIS precursor cells to
NSGCT. In addition, loss or inactivation of gene(s) located at
3q27–q28 possibly explains the inability of null-potent embryonal
carcinoma to differentiate into somatic or extra-embryonic tissue,
and deserves further study.
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